Alglucosidase alfa

Alglucosidase alfa (Myozyme) is a drug used to treat Glycogen storage disease type II (Pompe's disease). It is an analogue of acid alpha-glucosidase.

Some health plans have refused to pay for Myozyme, because it costs $300,000 a year for adults, and has only been approved by the F.D.A. for use in infants.